Clinical Trial Detail

NCT ID NCT03382899
Title Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 1)mall Cell Lung Cancer (Cypress 1)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors ARMO BioSciences
Indications

lung non-small cell carcinoma

Therapies

Pegilodecakin + Pembrolizumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.